OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (AIM) (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop ...
A study links COVID-19 infection to higher ME/CFS rates, supporting Ampligen's potential as a treatment for affected individuals. AIM ImmunoTech Inc. has commented on a recently published study in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results